An observational study in Pulmonary Arterial Hypertension, sponsored by United Therapeutics. Active, not recruiting at 41 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-02.
Sponsored by United Therapeutics · Observational
This prospective, observational, multicenter, patient registry will follow patients who are receiving treatment with Orenitram for the treatment of PAH for up to 78 weeks from Orenitram initiation
761 studies on the registry are indexed under Pulmonary Arterial Hypertension; 142 are open to participants now.
This study's planned enrollment of 300 is above the median of 100 across 197 observational studies indexed under Pulmonary Arterial Hypertension.
Browse Pulmonary Arterial Hypertension studies →United Therapeutics is the lead sponsor of 81 studies on the registry; 6 are open to participants now.
Of its 17 completed or terminated interventional studies of FDA-regulated products, 14 (82%) have results posted.
Counted across the registry records on this site, refreshed daily.
Patients are eligible if they have been receiving Orenitram for 182 or fewer days.
Patients are eligible for the registry if:
EXCLUSION CRITERIA
Patients are ineligible for the registry if:
Sustained-release oral tablets for three times daily (TID) administration in prostacyclin naive and prostacyclin transition patients
Drug: Oral treprostinil
Sustained-release oral tablets for TID administration
Also known as: Treprostinil diethanolamine, Treprostinil diolamine
Real-world use and tolerability of Orenitram in new starts and prostacyclin transition patients
Time frame: Baseline to Week 78
To assess treatment-related outcomes during routine clinical care.
eg, 6-Minute Walk Distance \[6MWD\], World Health Organization \[WHO\] Functional Class \[FC\]
Time frame: Baseline to Week 78
To observe the development, timing, severity, frequency, and treatment of prostacyclin-related adverse events (AEs) of interest
Time frame: Baseline to Week 78
Use of concomitant medications
Time frame: Baseline to Week 78
To evaluate information on clinical titration schedules implemented for transition to and from alternative prostacyclin-class therapies
Time frame: Baseline to Week 78
Healthcare resource utilization trends
Time frame: Baseline to Week 78
Health-related quality of life in PAH and treatment satisfaction
Time frame: Baseline to Week 78
To evaluate reasons for discontinuation of Orenitram
Time frame: Baseline to Week 78
To evaluate titration and dosing schedules of Orenitram
Time frame: Baseline to Week 78
Plan to share: No
No publications or documents are linked to this record.
This study is active, not recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Pulmonary Arterial Hypertension→
United Therapeutics